Folate-targeted therapeutic and imaging agents for cancer

Current Opinion in Chemical Biology

Volumn 13, Issue 3, 2009, Pages 256-262

  Low, Philip Stewart ^a   Kularatne, Sumith Anurasiri ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DEACETYLVINBLASTINE; EC145; EC17; FOLATE RECEPTOR; FOLIC ACID; PENTETATE INDIUM IN 111; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CANCER CELL; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; GAMMA SCINTIGRAPHY; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY CANCER; NONHUMAN; OSTEOARTHRITIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SOLID TUMOR; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; FOLIC ACID; HUMANS; NEOPLASMS; RECEPTORS, CELL SURFACE;

ANIMALIA;

EID: 67649849650     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2009.03.022     Document Type: Review

References (55)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008) 4808-4817
2. Rabatti D. The discovery of anti-angiogenic molecules: a historical review. Curr Pharm Des 15 (2009) 345-352
3. Jean G.W., and Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28 (2008) 742-754
4. Yan H., and Tram K. Glycotargeting to improve cellular delivery efficiency of nucleic acids. Glycoconj J 24 (2007) 107-123
5. Irache J.M., Salman H.H., Gamazo C., and Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5 (2008) 703-724
6. Corti A., Curnis F., Arap W., and Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 112 (2008) 2628-2635
7. Garanger E., Boturyn D., and Dumy P. Tumor targeting with RGD peptide ligand - design of new molecular conjugates for imaging and therapy of cancer. Anticancer Agents Med Chem 7 (2007) 552-558
8. Cho K., Wang X., Nie S., Chen Z., and Shin D. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14 (2008) 1310-1316
9. Gupta Y., Kohli D.V., and Jain S.K. Vitamin B12-mediated transport: a potential tool for tumor targeting of anti-neoplastic drugs and imaging agents. Crit Rev Ther Drug Carrier Syst 25 (2008) 347-379
10. Low P.S., Henne W.A., and Doorneweerd D.D. Discovery and development of folic-acid based receptor targeting for imaging and therapy of cancer and inflammatory disease. Acc Chem Res 41 (2008) 120-129. This review highlights the discovery and development of folate-targeted imaging and therapeutic agents for cancer and inflammatory diseases.
11. Salazar M.D., and Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26 (2007) 141-152. This paper summarizes the structure, function, distribution and recycling of folate receptors and FR-targeted therapeutic agents.
12. Zhao X., Li H., and Lee R.J. Targeted drug delivery via folate receptor. Expert Opin Drug Deliv 5 (2008) 309-319
13. Antony A.C. The biological chemistry of folate receptor. Blood 79 (1992) 2807-2820
14. Matherly L.H., Hou Z., and Deng Y. Human reduced folate carrier translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26 (2007) 111-128
15. Zhao R., Min S.H., Wang Y., Campanella E., Low P.S., and Goldman I.D. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Boil Chem 284 (2009) 4267-4274
16. Elnakat H., and Ratnam M. Distribution, functionality and gene reglation of folate receptor isoforms: Implications in targeted therapy. Adv Drug Deliv Rev 56 (2004) 1067-1084
17. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski Jr. V.R., and Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52 (1992) 3396-3401
18. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., and Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52 (1992) 6708-6711
19. Chancy C.D., Kekuda R., Huang W., Prassad P.D., Kuhnel J.M., Sirotnak F.M., Roon P., Ganapathy V., and Smith S.B. Expression and differential polarization of the reduced-folate transporte-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 275 (2000) 20676-20684
20. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., and Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 15 (2005) 284-293. This paper contains the most up-to-date data on FR expression in human cancers.
21. Ross R.F., Chaudhuri P.K., and Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines, physiological and clinical implications. Cancer 73 (1994) 2432-2443
22. Bueno R., Appasani K., Mercer H., Laster S., and Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelipma. J Thorac Cardiovasc Surg 121 (2001) 225-233
23. Nakashima-Matsushita A., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., and Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42 (1999) 1609-1616
24. Van der Heijden J.W., Oerlemans R., Dijkmans B.A., Qi H., van der Laken C.J., Lems W.F., Jackman A.L., Kraan Mc, Tak P.P., Ratnum M., et al. Folate receptor beta as a potential delivery route for novel folate antagonist to macrophage in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 60 (2009) 12-21
25. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J.X., and Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113 (2009) 438-446. This paper defines in detail the properties of activated macrophages that express FR-β. It also demonstrates that no other hematopoietic cell expresses FR. Finally, it demonstrates for the first time that rheumatoid arthritic joints can be identified with folate-targeted imaging agents.
26. Yamaguchi T., Hirota K., Nagahama K., Ohkawa K., Takahashi T., Nomura T., and Sakaguchi S. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27 (2007) 145-159
27. Spiegelstine O., Eudy J.D., and Finnell R.H. Identification of two putative novel folate receptor genes in humans and mouse. Gene 258 (2000) 117-125
28. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94 (2005) 2135-2146
29. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 26 (1999) 717-719
30. Ren Y., Tang J., Mok M.Y., Chan A.W., Wu A., and Lau C.S. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48 (2003) 2888-2897
31. Grip O., Janciauskiene S., and Lindgren S. Macrophages in inflammatory bowel disease. Curr Drug Targets Inflamm Allergy 2 (2003) 155-160
32. Gueler F., Park J.K., Rong S., Kirsch T., Lindschau C., Zheng W., Elger M., Fiebeler A., Fliser D., Luft F.C., et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170 (2007) 1192-1199
33. Sandoval R.M., Kennedy M.D., Low P.S., and Molitoris B.A. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 287 (2004) C517-C526
34. Leamon C.P., Reddy J.A., Vlahov I.R., Kleindl P.J., Vetzel M., and Westrick E. Synthesis and biological evaluation of EC140: a novel folate-targeted vinka alkaloid conjugate. Bioconjugate Chem 17 (2006) 1226-1232
35. Reddy J.A., Westrick E., Santhapuram H.R.K., Howard S.J., Miller M.L., Vetzel M., Vlahov I., Chari R.V.J., Goldmacher V.S., and Leamon C.P. Folate receptor-specific antitumor activity of EC131, a flate-maytansinoid conjugate. Cancer Res 67 (2007) 6376-6382
36. Reddy J.A., Dorton R., Westrick E., Dawson A., Smith T., Xu L.C., Vetzel M., Kleindl P., Vlahov I.R., and Leamon C.P. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67 (2007) 4434-4442. This article documents the use of a folate-desacetylvinblastine conjugate to selectively eliminate FR+ tumors from live mice without causing collateral damaged to normal tissues.
37. Leamon C.P., Reddy J.A., Vlahov I.R., Westrick E., Parker N., Nicoson J.S., and Vetzel M. Comparative preclinical activity of the folate-targeted vica alkaloid conjugates EC140 and EC145. Int J Cancer 121 (2007) 1585-1592
38. Leamon C.P., Reddy J.A., Vlahov I.R., Westrick E., Dawson A., Dorton R., Vetzel M., Santhapuram H.K., and Wang Y. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 4 (2007) 659-667
39. Leamon C.P., Reddy J.A., Vetzel M., Dorton R., Westrick E., Parker N., Wang Y., and Vlahov I. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res 68 (2008) 9839-9844
40. Leamon C.P., and Low P.S. Delovery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88 (1991) 5572-5576
41. Jackman A.L., Theti D.S., and Gibbs D.D. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv 56 (2004) 1111-1125
42. Turek J.J., Leamon C.P., and Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci 106 (1993) 423-430
43. Yang J., Chen H., Vlahov I.R., Cheng J.-X., and Low P.S. Evaluation of disulfide reduction during receptor-mediated endocytosis by FRET imaging. Proc Natl Am Soc 103 (2006) 13878-13977. This reference characterizes the itinerary of folate-drug conjugates following FR-mediated endocytosis and defines the intracellular compartment where the disulfide bond linking folate to its attached drug is cleaved. It also demonstrates that folate is sorted into a different endosome from the attached drug, and that folate and FR are recycled back to the plasma membrane while the released drug is retained inside the cell.
44. Chatterjee S., Smith E.R., Hanada K., Stevens V.L., and Mayer S. GPI anchoring leads to sphingolopid-dependent retention of endocytosed in the recycling endosomal compartment. EMBO J 20 (2001) 1583-1593
45. Paulos C.M., Reddy J.A., Leamon C.P., Turk M.J., and Low P.S. Ligand biding and kinetics of folate receptor recycycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 66 (2004) 1406-1414
46. Yang J., Chen H., Vlahov I.R., Cheng J.X., and Low P.S. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 321 (2007) 462-468
47. Lee R.J., Wang S., and Low P.S. Measurement of endosome pH following folate-mediated endocytosis. Biochem Biophys Acta 1312 (1996) 237-242
48. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 44 (2003) 700-707
49. Leamon C.P., Parker M.A., Vlahov I.R., Xu L.C., Reddy J.A., Vetzel M., and Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived 99mTc-based radiopharmaceutical. Bioconjugate Chem 13 (2002) 1200-1210
50. 111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem 8 (1997) 673-679
51. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., and Green M.A. Indium-111-DTPA-dlate as a potential folate-receptor-targeted radiopharmacetical. J Nucl Med 39 (1998) 1579-1585
52. Fisher R.E., Siegel B.A., Edell S.L., Oyesiku N.M., Morgenstern D.E., Messmann R.A., and Amato R.J. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 49 (2008) 899-906
53. Lu Y., and Low P.S. Folate targeting of haptens to cancer cell surfaces mediated immunotherapy of syngenic murine tumors. Cancer Immunol Immunother 51 (2002) 153-162. This paper describes a novel tumor targeted immunotherapy that marks a cancer cells with so many foreign haptens that it becomes highly recognized by the immune system.
54. Lu Y., Sega E., and Low P.S. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116 (2005) 710-719
55. Vlahov I.R., Santhapuram H.K., Kleindl P.J., Howard S.J., Stanford K.M., and Leamon C.P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part I: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16 (2006) 5093-5096